Corcept's Ovarian Cancer Drug Shows Promising Results in Phase 3 Trial
San Francisco, Monday, 31 March 2025.
Corcept Therapeutics’ relacorilant reduces disease progression by 30% in platinum-resistant ovarian cancer, improving survival. Shares surged 77% after announcing results on March 30, 2025.
Breakthrough Trial Results
In a significant advancement for ovarian cancer treatment, Corcept Therapeutics (NASDAQ: CORT) announced on March 30, 2025, that its Phase 3 ROSELLA trial met its primary endpoint. The study demonstrated that relacorilant, when combined with nab-paclitaxel chemotherapy, reduced the risk of disease progression by 30% compared to nab-paclitaxel alone (hazard ratio: 0.70; p-value: 0.008) [1][5]. The trial, which enrolled 381 patients across multiple continents, showed a median progression-free survival of 6.5 months for patients receiving the combination therapy, compared to 5.5 months for those on nab-paclitaxel alone [1].
Survival Benefits and Safety Profile
The interim analysis revealed compelling survival benefits, with patients receiving the combination therapy achieving a median overall survival of 16.0 months, compared to 11.5 months in the control group (hazard ratio: 0.69; p-value: 0.012) [1]. Importantly, relacorilant demonstrated a favorable safety profile, with no new safety signals observed during the trial [3]. This development is particularly significant for the approximately 20,000 women diagnosed annually with platinum-resistant ovarian cancer in the United States [5].
Market Impact and Future Plans
The market responded enthusiastically to the trial results, with Corcept’s stock price surging by 85% from $54.60 to $101 following the announcement [3]. The company has outlined its regulatory strategy, planning to submit a New Drug Application to U.S. regulators in Q3 2025 [5]. Dr. Alexander Olawaiye, director of gynecological cancer research at Magee-Womens Hospital and principal investigator for ROSELLA, has characterized these results as ‘an important advancement in the development of a treatment for patients with platinum-resistant ovarian cancer’ [3].
Next Steps and Clinical Implementation
Corcept plans to present the complete ROSELLA trial results at an upcoming medical conference later this year [1]. The company is simultaneously advancing relacorilant for other indications, having submitted a New Drug Application for endogenous hypercortisolism (Cushing’s syndrome) earlier in March 2025 [3]. According to Bill Guyer, PharmD, Corcept’s Chief Development Officer, these results position relacorilant as a potential new standard-of-care treatment for platinum-resistant ovarian cancer [5].